Paul Moorehead/LinkedIn
Aug 6, 2025, 10:47
Conquering Factor VIII Inhibitors: New Insights Into the ‘Devil’ of Hemophilia A Treatment Resistance
Flora Peyvandi posted on X:
”Exorcizing the devil of factor VIII inhibitors”
“For the Devil is a gentleman, and doesn’t keep his word” – G.K. Chesterton
In this issue of Blood Advances, Butera et al shed some light on the mystery of factor VIII (FVIII) inhibitors, the most diabolical complication of FVIII replacement therapy in patients with hemophilia A. Their work examined the impact of disulfide bonds on the antigenicity of the FVIII molecule, with possible implications for the understanding of immune responses to exogenous FVIII and for drug design.
Read the full article here.
Auothor: Paul C. Moorehead
Stay updated with Hemostasis Today.
-
Aug 25, 2026, 12:26Rahaf M. Altahan: Diagnosis and Management of Factor XIII Deficiency
-
Aug 25, 2026, 12:20Christodoulos Papadopoulos: Oral Anticoagulation Monotherapy in Chronic Coronary Syndrome
-
Aug 25, 2026, 12:17Ifeanyichukwu Ifechidere: Coagulation Knowledge in Cardiology
-
Aug 25, 2026, 12:14Annie Bauzon: Platelets – The Tiny Cells That Stop You From Bleeding
-
Aug 25, 2026, 12:10Marloes de Kovel: FVIII Exposure With Severe Haemophilia A on Emicizumab Prophylaxis
-
Aug 25, 2026, 11:59What Happens When the Next Generation of Hematologists Looks Elsewhere? – Global Hemophilia Report
-
Aug 25, 2026, 11:54Kimberly Jacobson: MSL Opportunity in Rare Blood and Bleeding Disorders
-
Aug 25, 2026, 11:48GPAS 2026 Advancing Access and Equity in Bleeding Disorders – WFH
-
Aug 25, 2026, 11:41Gregory Lip: Don’t Miss – €1,000 Mechanical Thrombectomy Grant